Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAO YIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1477909240
CMS profile
11334812
Location
FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,320.55

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,779.55 75
Consulting Fee $525.00 1
Education $16.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAO YIN

NPI 1477909240 · CMS profile ID 11334812

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477909240?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAO YIN, NPI 1477909240, CMS profile ID 11334812. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477909240?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHAO YIN, NPI 1477909240, CMS profile ID 11334812. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477909240?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHAO YIN, NPI 1477909240, CMS profile ID 11334812, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1477909240?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $2,320.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $23.9006/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078796407 CMS
Merck Sharp & Dohme LLC $18.9506/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141815267 CMS
Eisai Inc. $29.8606/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110735999 CMS
PFIZER INC. $14.1005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131918005 CMS
GENZYME CORPORATION $27.2505/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140014505 CMS
Genentech USA, Inc. $24.8605/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132986015 CMS
Daiichi Sankyo Inc. $29.5405/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500738 CMS
PFIZER INC. $16.0005/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131585840 CMS
Daiichi Sankyo Inc. $0.4105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500734 CMS
Daiichi Sankyo Inc. $12.9105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500736 CMS
Novartis Pharmaceuticals Corporation $23.7604/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087362132 CMS
Alexion Pharmaceuticals, Inc. $25.2204/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093885498 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.9704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144970785 CMS
Janssen Biotech, Inc. $32.9804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078796928 CMS
E.R. Squibb & Sons, L.L.C. $24.5504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101284372 CMS
Janssen Biotech, Inc. $24.5504/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078798312 CMS
Genentech USA, Inc. $31.3003/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132986011 CMS
Novartis Pharmaceuticals Corporation $19.2403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087362128 CMS
Celgene Corporation $29.3103/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101098804 CMS
Daiichi Sankyo Inc. $10.6203/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500726 CMS
PUMA BIOTECHNOLOGY, INC. $19.7703/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113857294 CMS
BeiGene USA, Inc. $19.4002/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120860989 CMS
Lilly USA, LLC $14.3802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136100296 CMS
Alexion Pharmaceuticals, Inc. $22.8002/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093957194 CMS
ABBVIE INC. $34.6401/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106376538 CMS
Janssen Biotech, Inc. $38.2401/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078798300 CMS
Daiichi Sankyo Inc. $14.1401/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089500728 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $335.74 9
PY2023 $725.72 31
PY2024 $2,320.55 77
PY2025 $1,366.66 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $395,423.24 113
PY2024 Principal investigator $28,150.10 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184279440
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/18/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769437
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/18/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769439
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/18/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769441
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/18/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769443
Principal investigator 1 Boehringer Ingelheim International GmbH $203.64 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769481
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769483
Principal investigator 1 Boehringer Ingelheim International GmbH $419.58 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769485
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769487
Principal investigator 1 Boehringer Ingelheim International GmbH $183.21 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769489
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769491
Principal investigator 1 Boehringer Ingelheim International GmbH $17.52 12/17/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769493
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/15/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769477
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/15/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769479
Principal investigator 1 Boehringer Ingelheim International GmbH $20,000.00 12/10/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769465
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/10/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769467
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/10/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769469
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714493
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714495
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715069
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715071
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715147
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715149
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715151
Principal investigator 1 PFIZER INC. $3,187.76 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715255
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715257
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Virginia Cancer Specialists PC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715323
Principal investigator 1 Exelixis Inc. $4,500.00 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386676
Principal investigator 1 Exelixis Inc. $1,500.00 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386678
Principal investigator 1 Exelixis Inc. $18,000.00 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386680
Principal investigator 1 Exelixis Inc. $3,000.00 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386682
Principal investigator 1 Exelixis Inc. $1,499.85 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386684
Principal investigator 1 Exelixis Inc. $5,000.00 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386686
Principal investigator 1 Exelixis Inc. $967.95 12/04/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386688
Principal investigator 1 Boehringer Ingelheim International GmbH $4,915.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769445
Principal investigator 1 Boehringer Ingelheim International GmbH $5,231.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769447
Principal investigator 1 Boehringer Ingelheim International GmbH $3,617.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769449
Principal investigator 1 Boehringer Ingelheim International GmbH $371.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769451
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769453
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769455
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769457
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769459
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769461
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769463
Principal investigator 1 Exelixis Inc. $1,500.00 12/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222386690
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/01/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769471
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/01/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769473
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/01/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769475
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $102,326.07 11/30/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220998395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184258039
Principal investigator 1 ABBVIE INC. $20,000.25 11/05/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS PC
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) No dispute reported 06/30/2026 1202522621
Principal investigator 1 Daiichi Sankyo Inc. $25.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318438
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318440
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318442
Principal investigator 1 Daiichi Sankyo Inc. $4.25 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318444
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318446
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318448
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318450
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318452
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318454
Principal investigator 1 Daiichi Sankyo Inc. $9.75 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318456
Principal investigator 1 Daiichi Sankyo Inc. $4.40 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318458
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318460
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318462
Principal investigator 1 Daiichi Sankyo Inc. $39.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318464
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318466
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318468
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318470
Principal investigator 1 Daiichi Sankyo Inc. $127.75 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318472
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318474
Principal investigator 1 Daiichi Sankyo Inc. $4.25 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318476
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318478
Principal investigator 1 Daiichi Sankyo Inc. $37.35 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318480
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318482
Principal investigator 1 Daiichi Sankyo Inc. $46.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318484
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318486
Principal investigator 1 Daiichi Sankyo Inc. $36.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318488
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318490
Principal investigator 1 Daiichi Sankyo Inc. $20.85 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318492
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318494
Principal investigator 1 Daiichi Sankyo Inc. $8.80 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318496
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318498
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318500
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318502
Principal investigator 1 Daiichi Sankyo Inc. $15.50 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318504
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
DS7300-202 No dispute reported 06/30/2026 1225318506
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,275.00 10/31/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185547073
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $51,163.03 10/31/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220998393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253891
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,450.56 10/03/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974916
Principal investigator 1 Deciphera Pharmaceuticals Inc. $158.08 10/03/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974920
Principal investigator 1 Deciphera Pharmaceuticals Inc. $44,370.00 10/03/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244885
Principal investigator 1 Deciphera Pharmaceuticals Inc. $70.00 09/29/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974598
Principal investigator 1 Deciphera Pharmaceuticals Inc. $70.00 09/29/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974603
Principal investigator 1 Deciphera Pharmaceuticals Inc. $70.00 09/29/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974609
Principal investigator 1 Deciphera Pharmaceuticals Inc. $70.00 09/29/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184213093
Principal investigator 1 ABBVIE INC. $30,719.00 07/02/2025 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS PC
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202494153
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769423
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769425
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769427
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769429
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769431
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769433
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 06/24/2025 Non-covered Recipient Entity
Virginia Cancer Specialists Fairfax
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220769435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 06/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,200.00 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184192009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184192011
Principal investigator 1 Genentech, Inc. $1,500.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC No dispute reported 06/30/2026 1211676381